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SUMMAry
The aim of this study was to establish the incidence, risk factors, and the management of pharyngocutaneous fistula (PCF) after primary and 
salvage total laryngectomy. A retrospective, match-paired analysis of 86 patients who developed fistula after total laryngectomy was carried 
out and compared with a control group of 86 patients without fistula, randomly selected from a pool of 352 total laryngectomies, performed 
between January 1999 to october 2014. The overall incidence of PCF in the series was 24.4%; we recorded rates of 19.0%, 28.6% and 
30.3% following primary total laryngectomy (PTl), salvage laryngectomy post-radiotherapy (rT-STl) and salvage laryngectomy post-
chemoradiotherapy (CrT-STl), respectively. Multivariate analysis revealed that the relative risk of fistula was respectively 2.47, 3.09 and 
7.69 for hypoalbuminaemia ≤3.5 g/dl, rT-STl and CrT-STl. An early onset of PCF within 10 postoperative days was recorded in case 
of salvage total laryngectomy. The management of PCF significantly differed between PTl, rT-STl and CTrT-STl, with exclusive con-
servative treatment for PTl (93.55%), while in the CrT-STl group surgical closure with regional flaps (58.82%) prevailed. Conservative 
management, adjuvant hyperbaric oxygen therapy and surgical closure were equally distributed in the rT-STl group. Thorough knowledge 
of patient-related risk factors and its prognostic value, allows the surgeon to better evaluate preventive strategies with the aim of minimising 
fistula formation, hospitalisation times and related costs.
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riASSUnTo
In questo studio sono state valutate l’incidenza, i fattori di rischio e le modalità di trattamento in pazienti con fistola faringocutanea dopo 
laringectomia totale primaria e di salvataggio. Nel periodo compreso tra gennaio 1999 e ottobre 2014, 352 pazienti affetti da carcinoma 
squamocellulare della laringe sono stati sottoposti a laringectomia totale. Il decosro postoperatorio di 86 pazienti è stato complicato 
dall’insorgenza di fistola fainrogcutanea. Questi sono stati comparati in uno studio caso-controllo con 86 pazienti selezionati tramite 
software, fra quelli che non avevano sviluppato la fistola salivare. L’incidenza globale di fistola dopo laringectomia totale è stata del 
24,4%, rispettivamente abbiamo registrato incidenze del 19,0%, del 28,6% e del 30,3% dopo laringectomia totale primaria, dopo ra-
dioterapia e dopo radiochemioterapia. L’analisi multivariata ha rivelato che per ipoalbuminemia ≤3,5 g/dL, per pregressa radioterapia 
e radiochemioterapia il rischio relativo di sviluppo di fistola è stato rispettivamente 2,47, 3,09 e 7,69. In caso di laringectomia totale di 
salvataggio abbiamo registrato una comparsa precoce della fistola entro i primi 10 giorni postoperatori. Le modalità di trattamento della 
fistola faringocutanea sono risultate essere significativamente differenti in caso di laringectomia totale primaria, dopo radioterapia e dopo 
radiochemioterapia. Infatti, mentre nel primo caso è stato sufficiente un trattamento di tipo conservativo (93,55%), dopo chemioradiotera-
pia ha prevalso il ricorso a tecniche chirurgiche ricostruttive con lembi regionali (58,82%). Nel caso dei pazienti radiotrattati, le opzioni 
terapeutiche della fistola sono risultate essere equamente distribuite tra quella medica, eventualmente con l’aggiunta dell’ossigenoterapia 
iperbarica, e quella chirurgica ricostruttiva. La conoscenza dei fattori di rischio soggettivi e il loro valore prognostico, permettono al 
chirurgo di pianificare le strategie preventive al fine di ridurre il rischio di formazione della complicanza e, conseguentemente, dei tempi 
di degenza e dei relativi costi.
PArolE ChiAVE: Fistola faringocutanea • Laringectomia totale di salvataggio • Fattori di rischio • Radiochemioterapia
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Introduction
The development of a pharyngocutaneous fistula repre-
sents a complication of total laryngectomy that is usu-
ally self-limiting. its management is thus mainly based 
on careful conservative treatment; however, at times, this 
complication can carry potentially devastating sequelae, 
and further surgery is required.
The incidence of pharyngocutaneous fistula has been re-
ported to be 14.3% (95% Ci 11-7-17.0) after primary total 
laryngectomy, increasing significantly to 22.8% (95% Ci 
18.3-27.4) and 34.1% (95% Ci 22.6-45.6) in case of pre-
vious radiotherapy or previous chemoradiotherapy 1. 
numerous risk factors, such as pre-existing comorbidi-
ties, smoke and alcohol abuse, pre- and postoperative 
haemoglobin and albumin values, tumour site and stage, 
concurrent neck dissection etc., have been implicated in 
fistula formation 2-13, although, the actual impact of these 
remains debatable.
in this retrospective study, we analysed potential risk 
factors for the development of postoperative pharyn-
gocutaneous fistula after total laryngectomy and de-
scribe our systematic approach in the management of 
this complication. 
Materials and methods
Between January 1999 and october 2014, 352 consecu-
tive total laryngectomies for laryngeal squamous cell car-
cinoma were performed at the otolaryngology Clinic of 
the department of Surgery and Translational Medicine of 
the University of Florence. The search was restricted to 
laryngeal SCC and to total laryngectomies without flap 
reconstruction.
one hundred and sixty-three patients (46.3%) underwent 
primary total laryngectomy (PTl), 133 (37.8%) under-
went salvage total laryngectomy after radiotherapy (rT-
STl), and 56 (15.9%) received salvage total laryngecto-
my after chemoradiotherapy (CrT-STl). in 31 patients, 
the procedure was extended to the pharynx (piriform si-
nus and/or base of tongue), and in PTl we also included 
salvage procedures after previous transoral laser or previ-
ous partial laryngectomy.
institutional review Board permission was obtained by 
the local committee. 
Pretreatment staging was corrected using the (UiCC)
TnM 7th edition based on the clinical charts 14.
The postoperative course of 86 patients was complicated 
by the onset of a pharyngocutaneous fistula; this group 
was matched and compared with a control cohort group 
of 86 patients without PCF, randomly selected within our 
series. groups were homogeneous for age and gender. 
Between groups we matched and compared risk factors 
for PCF, including smoke and alcohol habits, comorbidi-
ties, previous radiotherapy and chemoradiotherapy, pre- 
and postoperative haemoglobin (≤ 12.5 mg/dl) and albu-
min (≤ 3.5 g/dl), tumour site and T stage (T1-3 vs. T4a), 
n stage (n0 vs. n+), uni- or bilateral neck dissection and 
type of neck dissection [selective neck dissection (Snd), 
modified radical neck dissection (mrnd), radical neck 
dissection (rnd)], neck level Vi dissection. 
The surgical technique was standardised among all sur-
geons. laryngectomy included standard removal of the 
hyoid bone and infrahyoid muscles, pharyngeal closure 
was always performed in a single layer, with a “T” shaped 
suture line, using Vicryl (polyglactin 910) 3/4-0 sutures. 
Two suction drains were applied and generally removed 
when producing less than 15 cc in 24 hours. Antibiotic 
therapy with amoxicillin/clavulanate was generally start-
ed one day before surgery and continued for the following 
seven days. Skin sutures were removed on postoperative 
day 9. Enteral feeding through the nasogastric tube was 
started on the third postoperative day, and oral feeding 
was started on postoperative day 14 if contrast radio-
graphic study showed no signs of fistula. 
Statistical analysis
randomisation was carried out with the intel® digital ran-
dom number generator. A chi-square test was used to com-
pare discrete variables. A p value < 0.05 was considered 
statistically significant. Analysis was conducted using graph 
Pad software (graph Pad, San diego, CA). A logistic regres-
sion model was used on the significant risk factors to estimate 
the relative impact of fistula formation. Mcnemar’s test was 
used to assess time interval significance between variables 
within a cut-off time (10 days after intervention). data re-
garding fistula treatment were also collected and an AnoVA 
test was employed to compare different treatment modalities 
in the three patient groups (PTl, rT-STl, and CrT-STl). 
These tests were all conducted using STATA (Stata Corpora-
tion, College Station, TX).
Results
in this series, the incidence of PCF was 19% among patients 
receiving primary total laryngectomy, while it increased to 
28.6% and 30.3% for patients receiving salvage total laryn-
gectomy after radiotherapy and chemoradiotherapy.
The match-paired analysis for factors predisposing to 
PCF formation showed a statistical significant difference 
regarding comorbidities, salvage laryngectomy and post-
operative albumin values in the two groups (Tab. i).
Furthermore, pre- and postoperative haemoglobin values 
below 12.5 mg/dl and bilateral neck dissection with in-
clusion of level Vi showed a trend towards statistical sig-
nificance.
The assessment of the relative impact of independent 
variables was established using logistic regression analy-
sis on the most relevant risk factors: odds ratios for PCF 
development were 2.478 for postoperative albumin val-
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ues below 3.5g/dl (p=0.023), 3.072 for salvage Tl after 
radiotherapy (p=0.002) and 7.694 for salvage Tl after 
chemoradiotherapy (p=0.001) (Tab. ii).
Mean hospitalisation time for fistula group and control 
group was respectively 51.6 (19-250) and 19.8 (15-22) 
days, (p=0.0034). The mean time interval between total 
laryngectomy and fistula formation was 18.33 (3-180) 
days; patients submitted to primary total laryngectomy 
showed a mean time of PCF formation of 21.43 days, 
while for those who developed PCF after salvage proce-
dures was 15.19 days. risk factors that showed signifi-
cance at multivariate analysis were analysed with a Mc-
nemar test for early PCF formation, with a cut-off time of 
10 days after surgery, radiotherapy and chemoradiother-
apy tested positive for early fistula formation (Tab. iii). 
Fifty-four fistula patients (62.8%) were treated conserva-
tively (neck dressing, antibiotic therapy, PPi etc.), 15 pa-
tients (27.7%) received hyperbaric oxygen therapy and 
32 patients (37.2%) needed further surgery: of these, in 
17 cases (53%) surgical revision and primary closure was 
sufficient, while in the remaining 15 patients (47%) surgi-
cal repair was performed using pectoralis major myofas-
cial or myocutaneous flap transposition. Figure 1 displays 
our flowchart in the management of PCF.
Conservative treatment for PCF was the most frequent 
option for patients after PTl, CrT-STl patients were 
mostly treated with pectoralis major flap transposition, 
rT-STl patients were equally treated either with conserv-
ative treatment or conservative treatment plus hyperbaric 
oxygen therapy and surgical revision. 
Discussion
With the evolution of non-surgical organ preservation 
protocols for treatment of laryngeal and hypopharyngeal 
squamous cell carcinomas, total laryngectomy is increas-
ingly performed as salvage procedure. Wound compli-
cations and pharyngocutaneous fistula have become an 
increasing concern. Wound healing complications can 
have a multi-factorial origin including previous chemo-
radiotherapy, hypoalbuminaemia, hypohemoglobinaemia, 
neck dissection, tumour stage and site 2-13. 
our study showed that postoperative albumin level below 
3.5 g/dl, previous radiotherapy and chemoradiotherapy 
were significantly correlated with PCF formation. Because 
of the retrospective setting, we were unable to assess the 
impact of nutritional status in multivariate analysis. in fact, 
the albumin level in itself is an insufficient parameter, and 
the prognostic nutritional index, which is a combination of 
biochemical factors (serum albumin, transferrin), immune 
competence (total lymphocyte count, hypersensitivity skin 
tests) and anthropometric measurements (BMi, arm mus-
cle circumference, and skin fold thickness), would be more 
Table I. Patient, disease, treatment and pathology specimen-related fac-
tors predisposing to PCF formation. 
Variables Fistula 
Group 
(n = 86)
Control 
Group 
(n = 86)
p value
Smoke
   No
   Yes
18
68
27
59
p = ns
p = ns
Alcohol
   No
   Yes
50
36
47
39
p = ns
p = ns
Alcohol+Smoke 34 29 p = ns
Comorbidities 42 28 p = 0.0433
Previous RT 38 22 p = 0.0161
Previous CRT 17 4 p = 0.0042
Pharyngolaryngectomy 4 3 p = ns
Neck dissection (type)
   RND
   mRND
   SND
46
7
18
21
43
4
15
24
p = ns
p = ns
p = ns
p = ns
Neck dissection (side)
   Monolateral
   Bilateral
29
17
31
12
p = ns 
p = ns
Neck dissection+ VI level
   Monolateral
   Bilateral
10
7
8
1
p = ns
p = 0.0640
Preoperative haemoglobin ≤12.5 mg/dL 34 22 p = 0.0730
Postoperative haemoglobin ≤12.5 mg/dL 58 46 p = 0.0859
Preoperative albumin ≤3.5 g/dL 21 25 p = ns
Postoperative albumin ≤3.5 g/dL 28 14 p = 0.0204
T Stage II,III
T Stage IV
55
31
48
38
p = ns
p = ns
N Stage
   N0
   N+
42
44
37
49
p = ns
p = ns
T site
   Supraglottic
   Pharyngolarynx
   Glottic
   Transglottic
   Subglottic
30
4
44
3
5
26
6
51
2
1
p = ns
p = ns
p = ns
p = ns
p = ns
ns; not significant.
Table II. Multivariate analysis of PCF risk factors.
Risk factors p value Odds ratio (95% CI)
Comorbidities 0.191 1.584 (0.794-3.158)
Postoperative albumin ≤3.5 g/dL 0.023 2.478 (1.131-5.428)
Previous RT 0.002 3.072 (1.485-6.353)
Previous CRT 0.001 7.694 (2.338-25.323)
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appropriate. Moreover, in head and neck carcinoma, nu-
tritional status deteriorates during chemoradiotherapy or 
hyperfractionated rT  15 and this has been shown to have 
a negative effect on morbidity, mortality and survival 16 17. 
it is likely that the increased morbidity of surgery in pa-
tients receiving CrT-STl compared with patients of com-
parable T classification receiving PTl is due to impaired 
nutritional status as well as the direct toxic effects of 
chemoradiation on tissue healing.
The role of radiotherapy in the genesis of pharyngocutane-
ous fistula has been extensively described, and some authors 
report that there is no significant associations 18-22. in a re-
cent meta-analysis, Paydarfar et al. 23 showed that, although 
preoperative radiotherapy represented a significant relative 
risk (rr) of PCF formation, there was also heterogeneity of 
effects among studies; in fact, other radiotherapy-associated 
variables such as radiotherapy dose and time frame between 
the end of radiation and surgery, did not demonstrate an in-
creased rr. At multivariate analysis, the odds ratio for PCF 
formation after radiation was 3.072 (p=0.002), and fistula 
seemed to occur early (or=3.0909; within 10 days). 
Similar results have been reported by a small number of 
authors 19 24. Chemoradiotherapy showed an odds ratio of 
7.694 for fistula formation (p=0.001) with a high or=9.8 
for early onset. 
Assessment of fistula formation was proven by X-ray 
swallow study, after two weeks postoperatively (Fig. 1). 
Some authors advocate the scintigraphic analysis as an 
objective and non-invasive tool to precisely identify the 
presence of pharyngocutaneous fistula and location of its 
internal orifice and to monitor its spontaneous closure 25.
our study is in agreement with the findings from the meta-
analysis of Sayles et al., where chemoradiotherapy seems 
to increase the risk of major wound complications more 
than radiotherapy alone. Furthermore, concurrent chemo-
radiotherapy protocols offers superior locoregional control 
at the expense of more frequent wound complications in the 
event of salvage surgery than induction chemotherapy fol-
lowed by radiotherapy 1. newman reported similar rates of 
PCF between patients receiving rT alone or more intensive 
therapy with either sequential or concomitant chemoradio-
therapy 26. Aires et al. found no significant differences be-
tween PTl and CrT-STl in terms of PCF development 27.
regarding PCF treatment, the results from our observational 
study pointed out that in PTl patients conservative therapy 
is almost exclusive, while pectoralis major flap transposition 
prevails in CrT-STl patients who develop fistula. in our se-
ries, the management of PCF in rT-STl was equally distrib-
uted among conservative treatment +/- hyperbaric oxygen 
therapy and revision surgery (Tab. iV). hyperbaric oxygen 
therapy improves wound healing, although the data do not 
suggest that it promotes short-term growth of cancer 28, and 
thus its use remains controversial. We believe that for salvage 
patients who cannot receive further adjuvant radiotherapy its 
use is well justified and highly effective since in all cases it 
eventually promotes complete healing. 
Early revision surgery with pectoralis major flap transposi-
tion was employed in case of major wound breakdown with 
vessel exposure and in case of evidence of fistula progres-
sion in CrT-STl patients, otherwise surgical revision with 
or without flap transposition was undertaken after persis-
tence of the fistula despite 3 weeks of conservative therapy. 
The pectoralis major flap can be harvested as a myofascial 
or myocutaneous flap  29 30. in general, at re-exploration, 
the pharyngeal mucosa is oedematous and fragile so that 
Table III. McNemar test for the risk factors related time interval impact on PCF formation.
Risk factors Exact McNemar significance probability Odds ratio 95% CI
Postoperative albumin ≤3.5 g/dL 0.7283 0.8333 0.3909-1.7509
Radiotherapy 0.0008 3.0909 1.5292-6.7626
Radiochemotherapy 0.00004 9.8 3.9260-31.5173
Fig. 1. Fistula treatment flow-chart.
Table IV. ANOVA for fistula treatments in PTL, RT-STL and CRT-STL groups. 
Fisher’s exact= 0.000.
Med Med+HbO Surgical 
revision
PM flap Total
PTL
%
29
93.55
1
3.23
1
3.23
0
0.00
31
100.00
STL-RT
%
7
18.42
14
36.84
12
31.58
5
13.16
38
100.00
STL-CTRT
%
2
11.76
1
5.88
4
23.53
10
58.82
17
100.00
Total
%
38
44.19
16
18.60
17
19.77
15
17.44
86
100.00
MED = medication, HbO = Hyperbaric Oxygen, PM = pectoralis major
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primary closure is feasible and wise only when the defect 
is minimal and direct suture will not produce excessive 
tension. in all other cases, the myofascial transposition of 
the flap is the preferred method, and the muscle is sutured 
inlay around the defect ensuring a tight closure. The my-
ocutaneous transposition is used only in rare cases of large 
pharyngeal breakdown with major tissue loss/necrosis of 
the pharyngeal mucosa. in these cases, the skin paddle, su-
tured inlay, will prevent pharyngeal stenosis that could oc-
cur more easily with a large myofascial inlay placement. if 
the necrosis also involves the central portion of the skin of 
the neck, we recommend to address the pharyngeal closure 
as described above and to provide outer skin reconstruction 
using a split thickness skin graft over the pectoralis major 
muscle that will be sutured inlay to the outer skin defect. 
in our opinion, pectoralis major flap transposition is the 
most efficient option since it is easy and quick to harvest 
and rotate, and has been demonstrated to be reliable even in 
hostile recipient sites 31 32. Furthermore, it does not require 
postoperative monitoring 33 and is cost effective 29. 
one minor disadvantage is the morbidity associated with 
loss of the pectoralis major muscle function especially in 
case of concomitant shoulder dysfunction following neck 
dissection 30 34-36. 
Based on our retrospective analysis, the incidence of PCF 
after previous rT or CrT was 29.1% (55 of 189), and the 
incidence of salvage laryngectomies requiring a flap trans-
position was 7.9% (15 of 189). We do not suggest to rou-
tinely harvest flaps in case of salvage total laryngectomies, 
although this seems reasonable after previous chemoradia-
tion in patients with comorbidities and low preoperative al-
bumin values. in these cases, we would recommend a my-
ofascial transposition of the pectoralis major flap overlay 
that is placed over the suture line of the primary pharyngeal 
closure to protect the suture and overlying skin of the neck.
Some authors recently described the use of the myofascial 
infrahyoid flap for defects following total laryngectomy  37, 
despite our enthusiastic experience with this reconstructive 
method 38-42, we always remove the infrahyoid muscles during 
total laryngectomy for oncologic reasons. Furthermore, we do 
not believe that this flap can represent a valid solution in the 
standard management of PCF because of the relative contrain-
dication represented by previous radiotherapy, and because 
this flap always needs to be harvested during ablative surgery 
and not when PCF appears in the postoperative course. 
Unfortunately, there is no evidence that mechanical sta-
pler pharyngeal closure might reduce fistula formation in 
high risk cases 43.
We currently continue to assess serum albumin, transfer-
rin, total lymphocyte count and BMi and we are testing 
other anthropometric parameters to better establish the 
time for surgery and identify easy-to-obtain parameters 
during follow-up consultations. We are also trying to im-
prove the preoperative nutritional status by integrating 
with oral impact® (nestlé, Vevey, Switzerland) 1000 ml 
(1000 kcal) per day plus usual diet for 5-7 days prior to 
surgery, as suggested by our nutritionists. however, we 
have data in this regard at the time of writing.
The limitations of this study are mainly represented by its 
retrospective setting. Even if the cohort of patients with 
PCF is relatively small (86 cases), this represents a single 
institution experience over the last 15 years. Using soft-
ware, we tried to avoid other biases by random assign-
ment of patients to the control group.
Conclusions
This study confirms that postoperative albumin values 
below 3.5 g/dl, previous radiotherapy and chemoradio-
therapy are significant predictors of PCF. Conservative 
treatment is advisable for PCF developing in non-(chemo)
radiated patients, hyperbaric oxygen therapy is effective as 
adjuvant treatment after previous radiotherapy, and most 
PCF developing in chemoradiated patients tend to progress 
and need flap coverage to avoid devastating outcomes.
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